Interleukin-18 as a potential target in inflammatory arthritis.
Gracie
J A
JA
University of Glasgow, Glasgow, UK. j.a.gracie@clinmed.gla.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D002908:Chronic Disease; D016207:Cytokines / Q000276:immunology; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D036341:Intercellular Signaling Peptides and Proteins; D020382:Interleukin-18 / Q000276:immunology*; D058919:Purinergic P2 Receptor Antagonists; D058486:Receptors, Purinergic P2X7; D015843:Serpins / Q000627:therapeutic use; D014764:Viral Proteins
D000911:Antibodies, Monoclonal; D016207:Cytokines; D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; D020382:Interleukin-18; C546468:P2RX7 protein, human; D058919:Purinergic P2 Receptor Antagonists; D058486:Receptors, Purinergic P2X7; D015843:Serpins; D014764:Viral Proteins; C118370:interleukin-18 binding protein; C074641:interleukin-1beta-converting enzyme inhibitor